Industry News
Bio21 Institute opens today
Australia's newest research institute, the AUD$100 million Bio21 Institute, based at the University of Melbourne, officially opened its doors today. [ + ]
Avantogen to co-develop genital herpes vaccine
Avantogen (ASX:ACU), formerly known as Australian Cancer Tehcnology, is to team up with the University of Alabama at Birmingham (UAB) to conduct a preclinical study to develop a new therapeutic vaccine for herpes simplex virus type 2 (HSV-2). [ + ]
BioProspect claims success in termite trial
The tract of bushland near Narrandera, in southern NSW, where Brisbane natural pesticide developer BioProspect (ASX:BPO) is field-trialling its promising termiticide AP778 teems with voracious termites. [ + ]
Agenix revises loss, details ThromboView plans
Brisbane's Agenix (ASX:AGX, NASDAQ:OTC:AGXLY) has forecast a lower full year loss for the year ended June 30 of between AUD$12.3 million and $12.8 million, compared with a $14.3 million loss last year. [ + ]
FDA backs IDT thalidomide facility
The Institute of Drug Technology (ASX:IDT) has been granted US Food and Drug Administration (FDA) approval to supply commercial quantities of Thalomid (thalidomide) to its US-based global biopharmaceutical client Celgene. [ + ]
Pharma-sponsored trial result reporting biased: report
A survey of Australian medical research specialists has found that bias and manipulation in reporting of clinical trial results are rife when the trials are sponsored by pharmaceutical companies. [ + ]
Australian, Japanese synchrotrons to partner
Japan's SPring-8, the world's largest synchrotron, has signed a new partnership with the Australian Synchrotron to share expertise and develop new technology. [ + ]
Experts say government must crank up medical research investment
Australia government must ramp up its investment in health and medical research to secure a strong, enduring, sustainable economic future according to Australian Graduate School of Management innovation and biotechnology expert, Professor Michael Vitale, and CEO of Research Australia, Dr Christine Bennett.
[ + ]Metabolic unveils obesity drug trial details
Melbourne-based Metabolic Pharmaceuticals (ASX:MBP) has clarified details of a previously announced Phase IIb trial of its anti-obesity drug AOD9604, with recruitment expected to commence in September or October this year. [ + ]
Biotech stocks steadied in May: Intersuisse
While biotechnology stocks have suffered in the first five months of 2005 -- with the Intersuisse biotechnology index showing a 23 per cent fall since December 31 -- the index stabilised in May with a 0.28 per cent gain. [ + ]
Research Australia calls on govt to ramp up funding
Australia must ramp up its investment in health and medical research to ensure its future prosperity, said Research Australia CEO Dr Christine Bennett and Australian Graduate School of Management professor Michael Vitale in a joint paper published this week in the Medical Journal of Australia. [ + ]
FDA advances Neuren's Phase III to next year
NZ-based Neuren (ASX:NEU) has received confirmation from the US Food and Drug Administration (FDA) that the company can bypass a previously planned Phase IIb study for its lead drug Glypromate and advance directly to a major Phase III efficacy study. [ + ]
We're open for business: CSIRO exec
The new executive director of CSIRO's business development team, Nigel Poole, is on the campaign trail, seeking to convince the business world that the organisation is open for business. [ + ]
On the nose warnings
BOC Scientific has available a package called AirSurance. The product range includes Detectagas and Stench Gas mixtures which together monitor and alert workers to unsafe gas levels.
[ + ]Board changes at Bone
Former AustCancer CEO Paul Hopper has joined the board of Perth-based Bone Medical (ASX:BNE), among other changes at the company, including the resignation of Michael Perrott from the board. [ + ]
